FDA Approves Pregabalin ANDA219593 by Unichem
The FDA has approved the Abbreviated New Drug Application (ANDA) for Pregabalin submitted by Unichem.
Published: July 11, 2026
Updated: July 11, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Pain Management
Asset: Unichem
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Unichem
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Unichem's generic Pregabalin introduces significant competition in the pain management market. This could lead to pricing pressures and market share erosion for existing branded products, necessitating strategic adjustments from portfolio teams.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timing and pricing strategies from Unichem and competitors.
Related companies & assets
Assets
Sources & Humanexa intelligence
Source links
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.